About X-Ceptor Therapeutics
X-Ceptor Therapeutics is a Healthcare company based in San Diego (United States) founded in 1999, and was acquired by Exelixis in September 2004. Nuclear receptor modulating small molecule drugs for metabolism and cardiovascular diseases. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its competitors include Portola Pharma, MyoKardia and Cellino; 3 of its 3 listed competitors have raised funding.
Company details
X-Ceptor Therapeutics was founded in 1999 in San Diego, United States, and operated in the biotechnology sector. Small molecule therapeutics were developed to modulate nuclear receptors linked to cholesterol metabolism and cardiovascular conditions. A reverse endocrinology method was employed to validate targets, establish disease proof-of-concept, and advance preclinical candidates. The company was acquired by Exelixis in September 2004 for 22.3 million in cash and stock.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website x-ceptor.com
- Acquired by Exelixis (Sep 2004)
Funding Insights of X-Ceptor Therapeutics
- Total Rounds 2
- Investors Count 3
All 2 funding rounds of X-Ceptor Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 1999 | Series B | – | – | ||
| Jun 1999 | Series B | – | – |
4 investors in total: 4 institutional.
Investors in X-Ceptor Therapeutics
X-Ceptor Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Exelixis, Ligand Pharmaceuticals and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Pharmaceutical drugs are manufactured and developed in the United States. | 1987 | ligand.com | San Diego, United States | |
Small molecule drugs for cancer treatment are developed. | 1994 | exelixis.com | San Francisco, United States |
Investor details for X-Ceptor Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of X-Ceptor Therapeutics
4 dated milestones of X-Ceptor Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded X-Ceptor Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series B,.
- Exit Acquired by Exelixis.
Competitors of X-Ceptor Therapeutics
X-Ceptor Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Portola Pharma, MyoKardia and Cellino.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies |
Detailed competitors of X-Ceptor Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as X-Ceptor Therapeutics (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about X-Ceptor Therapeutics
Complete news archive for X-Ceptor Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about X-Ceptor Therapeutics
X-Ceptor Therapeutics was founded in 1999.
X-Ceptor Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
X-Ceptor Therapeutics was founded in 1999 in San Diego, United States, and operated in the biotechnology sector. Small molecule therapeutics were developed to modulate nuclear receptors linked to cholesterol metabolism and cardiovascular conditions. A reverse endocrinology method was employed to validate targets, establish disease proof-of-concept, and advance preclinical candidates. The company was acquired by Exelixis in September 2004 for 22.3 million in cash and stock.
X-Ceptor Therapeutics's top competitors include Cellino, MyoKardia and Portola Pharma.
X-Ceptor Therapeutics has 4 investors. Key investors include Exelixis, Ligand Pharmaceuticals, Farallon Capital Management, and Gimv.
Yes. X-Ceptor Therapeutics was acquired by Exelixis in September 2004.